SHIAO-PEI WEATHERS

TitleAssistant Professor
InstitutionMD Anderson
DepartmentNeuro-Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Nelson BE, Roszik J, Ahmed J, Barretto CMN, Nardo M, Campbell E, Johnson AM, Piha-Paul SA, Oliva ICG, Weathers SP, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer. 2024 03 26; 23(1):64. PMID: 38532456; PMCID: PMC10964523.
      Citations:    Fields:    Translation:Humans
    2. Gubbiotti MA, Weinberg JS, Weathers SP, Dasgupta P, Tom MC, Aldape K, Quezado M, Abdullaev Z, Huse JT, Ballester LY. An incidental finding of a high-grade glioma with pleomorphic and pseudopapillary features (HPAP) with PBRM1 mutation. J Neuropathol Exp Neurol. 2024 Jan 19; 83(2):139-141. PMID: 38164987.
      Citations:    Fields:    Translation:Humans
    3. Nelson BE, Reddy NK, Huse JT, Amini B, Nardo M, Gouda M, Weathers SP, Subbiah V. Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma. NPJ Precis Oncol. 2023 May 25; 7(1):47. PMID: 37231247; PMCID: PMC10212928.
      Citations:    
    4. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032. PMID: 37114244; PMCID: PMC10129387.
      Citations:    
    5. Milbury K, Whisenant M, Weathers SP, Malliaha S, Snyder S, Jackson N, Li J, Li Y, Silva RF, Shih YT, Cohen L. Dyadic versus individual delivery of a yoga program for family caregivers of glioma patients undergoing radiotherapy: Results of a 3-arm randomized controlled trial. Cancer Med. 2023 03; 12(6):7567-7579. PMID: 36468605; PMCID: PMC10067051.
      Citations:    Fields:    Translation:Humans
    6. Groot J, Ott M, Wei J, Kassab C, Fang D, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, Najem H, DeCuypere M, Heimberger AB. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87. PMID: 35575067; PMCID: PMC9134932.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Capone S, Ketonen L, Weathers SP, Subbiah V. Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation. JCO Precis Oncol. 2022 04; 6:e2100371. PMID: 35507888; PMCID: PMC9200395.
      Citations:    Fields:    Translation:Humans
    8. Rogers JL, De La Cruz Minyety J, Vera E, Acquaye AA, Weinberg JS, Armstrong TS, Weathers SS, Pay?n SS. Assessing mobility in primary brain tumor patients: A descriptive feasibility study using two established mobility tests. Neurooncol Pract. 2022 May; 9(3):219-228. PMID: 35601968; PMCID: PMC9113321.
      Citations:    
    9. Kroll JL, Kim S, Cho D, Weathers SP, Chen AB, Smith G, Bruera E, Milbury K. Financial distress and its associated burden in couples coping with an advanced cancer. Support Care Cancer. 2022 May; 30(5):4485-4495. PMID: 35112209.
      Citations:    Fields:    Translation:Humans
    10. Harrison RA, Ou A, Naqvi SMAA, Naqvi SM, Weathers SS, O'Brien BJ, de Groot JF, Bruera E. Aggressiveness of care at end of life in patients with high-grade glioma. Cancer Med. 2021 12; 10(23):8387-8394. PMID: 34755486; PMCID: PMC8633215.
      Citations: 2     Fields:    Translation:Humans
    11. Weathers SP, Rood-Breithaupt J, de Groot J, Thomas G, Manfrini M, Penas-Prado M, Puduvalli VK, Zwingelstein C, Yung WKA. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab141. PMID: 34693288; PMCID: PMC8528265.
      Citations:    
    12. Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M, Garcia MM. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab079. PMID: 34377987; PMCID: PMC8350154.
      Citations: 1     
    13. Wang M, Jain P, Chi TL, Chen SE, Heimberger A, Weathers SP, Zheng L, Rao AV, Rossi JM. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J Immunother Cancer. 2020 10; 8(2). PMID: 33067318; PMCID: PMC7570235.
      Citations: 2     Fields:    Translation:Humans
    14. Sen S, Tanaka R, Khatua S, Zaky W, Janku F, Penas-Prado M, Weathers SP, Behrang A, Roszik J, Subbiah V. Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors. Cold Spring Harb Mol Case Stud. 2020 08; 6(4). PMID: 32843426; PMCID: PMC7476413.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    15. Aaroe AE, Majd N, Weathers SP, de Groot JF. Potential neurologic and oncologic implications of the novel coronavirus. Neuro Oncol. 2020 07 07; 22(7):1050-1051. PMID: 32296828; PMCID: PMC7184395.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    16. Trifiletti DM, Malouff TD, McGovern SL, Weathers SP, Wang TJC, Lassman AB, Cahill DP, Shih HA, Brown PD. Repeat Radiation in the Brain: Managing Patients With Locally Recurrent Glioma. Semin Radiat Oncol. 2020 07; 30(3):218-222. PMID: 32503786.
      Citations:    Fields:    Translation:Humans
    17. Noticewala SS, Ludmir EB, Bishop AJ, Chung C, Ghia AJ, Grosshans D, McGovern S, Paulino AC, Wang C, Woodhouse KD, Yeboa DN, Prabhu SS, Weathers SP, Das P, Koong AC, McAleer MF, Li J. Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk. Adv Radiat Oncol. 2020 Jul-Aug; 5(4):743-745. PMID: 32775785; PMCID: PMC7251361.
      Citations: 6     
    18. Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577. PMID: 32299815; PMCID: PMC9347965.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    19. de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549. PMID: 31755915; PMCID: PMC7158647.
      Citations: 41     Fields:    Translation:HumansCells
    20. Milbury K, Weathers SP, Durrani S, Li Y, Whisenant M, Li J, Lim B, Weinberg JS, Kesler SR, Cohen L, Bruera E. Online Couple-Based Meditation Intervention for Patients With Primary or Metastatic Brain Tumors and Their Partners: Results of a Pilot Randomized Controlled Trial. J Pain Symptom Manage. 2020 06; 59(6):1260-1267. PMID: 32061834.
      Citations: 3     Fields:    Translation:Humans
    21. Joseph J, Nathenson MJ, Trinh VA, Malik K, Nowell E, Carter K, Weathers SP, Demetri GD, Araujo D, Conley AP. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. J Immunother Cancer. 2019 11 08; 7(1):296. PMID: 31703609; PMCID: PMC6842215.
      Citations: 6     Fields:    Translation:HumansCells
    22. Kesler SR, Harrison RA, Petersen ML, Rao V, Dyson H, Alfaro-Munoz K, Weathers SP, de Groot J. Pre-surgical connectome features predict IDH status in diffuse gliomas. Oncotarget. 2019 Nov 05; 10(60):6484-6493. PMID: 31741712; PMCID: PMC6849657.
      Citations: 3     Fields:    
    23. Majd N, Weathers SP, de Groot J. Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases? Neuro Oncol. 2019 11 04; 21(11):1344-1345. PMID: 31515554; PMCID: PMC6827831.
      Citations:    Fields:    Translation:Humans
    24. Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol. 2019 Oct; 145(1):97-105. PMID: 31456142; PMCID: PMC7241441.
      Citations: 40     Fields:    Translation:Humans
    25. Acquaye AA, Vera E, Williams LA, Gilbert MR, Weathers SP, Armstrong TS, Pay?n SS. Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. J Patient Rep Outcomes. 2019 Aug 23; 3(1):58. PMID: 31444579; PMCID: PMC6708028.
      Citations: 1     
    26. Milbury K, Li J, Weathers SP, Shih T, Malliaha S, Li Y, Cohen L. A research protocol for a pilot, randomized controlled trial designed to examine the feasibility of a dyadic versus individual yoga program for family caregivers of glioma patients undergoing radiotherapy. Pilot Feasibility Stud. 2019; 5:95. PMID: 31367462; PMCID: PMC6657047.
      Citations:    
    27. Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer. 2019 05; 112:83-93. PMID: 30951926.
      Citations: 7     Fields:    Translation:Humans
    28. Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 05; 18(5):991-1000. PMID: 30926639; PMCID: PMC6497568.
      Citations: 5     Fields:    Translation:HumansCells
    29. Hamouda D, Weathers SP, Kumar VA, Nascimento FA. Stroke-like migraine attacks after radiation therapy (SMART) syndrome. Arq Neuropsiquiatr. 2019 03; 77(3):215. PMID: 30970135.
      Citations:    Fields:    Translation:HumansPHPublic Health
    30. Weathers SP, Epner DE. Rookie. J Clin Oncol. 2019 03 20; 37(9):751-753. PMID: 30742562.
      Citations:    Fields:    Translation:Humans
    31. Milbury K, Li J, Weathers SP, Mallaiah S, Armstrong T, Li Y, Bruera E, Cohen L. Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers. Neurooncol Pract. 2019 Jul; 6(4):311-320. PMID: 31386042; PMCID: PMC6660820.
      Citations: 7     
    32. Harrison RA, Nam JY, Weathers SP, DeMonte F. Intracranial dural, calvarial, and skull base metastases. Handb Clin Neurol. 2018; 149:205-225. PMID: 29307354.
      Citations: 3     Fields:    Translation:Humans
    33. Weathers SS, Gilbert MR. Toward Personalized Targeted Therapeutics: An Overview. Neurotherapeutics. 2017 04; 14(2):256-264. PMID: 27995437; PMCID: PMC5398979.
      Citations: 11     Fields:    Translation:Humans
    34. Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB. Tumor Vaccines for Malignant Gliomas. Neurotherapeutics. 2017 04; 14(2):345-357. PMID: 28389997; PMCID: PMC5398993.
      Citations: 21     Fields:    Translation:HumansAnimals
    35. Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25; 7(43):69466-69478. PMID: 27579614; PMCID: PMC5342491.
      Citations: 9     Fields:    Translation:HumansCells
    36. Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol. 2016 09; 129(3):487-494. PMID: 27406589; PMCID: PMC5021605.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    37. Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66. PMID: 27370400; PMCID: PMC5035527.
      Citations: 76     Fields:    Translation:HumansCells
    38. Gatson NT, Weathers SP, de Groot JF. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. CNS Oncol. 2016; 5(1):11-26. PMID: 26670466; PMCID: PMC6078156.
      Citations: 8     Fields:    
    39. Weathers SP, de Groot J. VEGF Manipulation in Glioblastoma. Oncology (Williston Park). 2015 Oct; 29(10):720-7. PMID: 26470893.
      Citations: 36     Fields:    Translation:Humans
    40. Weathers SP, Gilbert MR. Current challenges in designing GBM trials for immunotherapy. J Neurooncol. 2015 Jul; 123(3):331-7. PMID: 25577401.
      Citations: 16     Fields:    Translation:Humans
    41. Weathers SP, Gilbert MR. Advances in treating glioblastoma. F1000Prime Rep. 2014; 6:46. PMID: 24991423; PMCID: PMC4047946.
      Citations: 20     
    42. Weathers SP, de Groot J. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep. 2014 May; 14(5):443. PMID: 24652451.
      Citations: 8     Fields:    Translation:HumansAnimals
    43. Weathers SP, Kotagal V, Bohnen NI, Chou KL. Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease. Parkinsonism Relat Disord. 2014 Jan; 20(1):13-6. PMID: 24070538; PMCID: PMC3946835.
      Citations: 4     Fields:    Translation:HumansCells
    44. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 1-8.
    45. Advances in treating glioblastoma. F1000Prime Reports. 6.
    46. Immune checkpoint blockade as a potential therapeutic target. Neuro-Oncology. 18:1357-1366.
    47. VEGF manipulation in glioblastoma. ONCOLOGY (United States). 29:720-727.
    48. Toward Personalized Targeted Therapeutics. Neurotherapeutics. 1-9.
    49. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 7:69466-69478.
    WEATHERS's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (158)
    Explore
    _
    Co-Authors (58)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _